clinical trial · NCT06008938
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
CSL Behring·—·recruiting·n = 500
Hemophilia BHEMGENIXFactor IX (FIX)
brief summary
This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.
started
Jun 15, 2023
primary completion
Aug 1, 2043
completion
Aug 1, 2043
last updated
Feb 19, 2026
official title
An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol